However, we can speculate that in a population of morbid obese patients, where adiponectin levels are already extremely low and associated with NAFLD, the correlation with more severe disease such as NASH is weakened. This evidence concerns the gene ADIPOQ and metabolic dysfunction-associated steatohepatitis.